Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
- 25 January 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (6), 2503-2508
- https://doi.org/10.1073/pnas.0910649107
Abstract
Paclitaxel has emerged as a front line treatment for aggressive malignancies of the breast, lung, and ovary. Successful therapy of cancer is frequently undermined by the development of paclitaxel resistance. There is a growing need to find other therapeutic targets to facilitate treatment of drug-resistant cancers. Using a proteomics approach, elevated levels of Prohibitin1 (PHB1) and GSTπ were found associated with paclitaxel resistance in discrete subcellular fractions of two drug-resistant sublines relative to their sensitive sublines. Immunofluorescence staining and fractionation studies revealed increased levels of PHB1 on the surface of resistant cell lines. Transiently silencing either PHB1 or GSTπ gene expression using siRNA in the paclitaxel-resistant cancer cell sublines partially sensitized these cells toward paclitaxel. Intriguingly, silencing PHB1 but not GSTπ resulted in activation of the intrinsic apoptosis pathway in response to paclitaxel. Similarly, stably silencing either PHB1 or GSTπ significantly improved paclitaxel sensitivity in A549TR cells both in vitro and in vivo. Our results indicate that PHB1 is a mediator of paclitaxel resistance and that this resistance may depend on the cellular localization of the protein. We suggest PHB1 as a potential target for therapeutic strategies for the treatment of drug-resistant tumors.Keywords
This publication has 45 references indexed in Scilit:
- Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosisInternational Journal of Cancer, 2008
- Posttranslational modifications of Bcl2 family members-a potential therapeutic target for human malignancyFrontiers in Bioscience-Landmark, 2006
- Proteomic Analysis of Proteins Associated with Lipid Droplets of Basal and Lipolytically Stimulated 3T3-L1 AdipocytesPublished by Elsevier BV ,2004
- Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigensOncogene, 2004
- Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repressionOncogene, 2002
- Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosisOncogene, 2002
- Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteinsThe EMBO Journal, 2000
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.JCI Insight, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996
- Prohibition gene is overexpressed but not mutated in rat bladder carcinomas and cell linesCancer Letters, 1994